JP6523634B2 - Thrombus preventive and therapeutic agent and method for producing the same - Google Patents
Thrombus preventive and therapeutic agent and method for producing the same Download PDFInfo
- Publication number
- JP6523634B2 JP6523634B2 JP2014167862A JP2014167862A JP6523634B2 JP 6523634 B2 JP6523634 B2 JP 6523634B2 JP 2014167862 A JP2014167862 A JP 2014167862A JP 2014167862 A JP2014167862 A JP 2014167862A JP 6523634 B2 JP6523634 B2 JP 6523634B2
- Authority
- JP
- Japan
- Prior art keywords
- extract
- alcohol solution
- blood
- therapeutic agent
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000007536 Thrombosis Diseases 0.000 title claims description 25
- 239000003814 drug Substances 0.000 title claims description 21
- 229940124597 therapeutic agent Drugs 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 230000003449 preventive effect Effects 0.000 title claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 50
- 239000000284 extract Substances 0.000 claims description 44
- 239000000843 powder Substances 0.000 claims description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 claims description 14
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 claims description 14
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 238000000605 extraction Methods 0.000 claims description 11
- 241000196324 Embryophyta Species 0.000 claims description 8
- 240000008976 Pterocarpus marsupium Species 0.000 claims description 7
- 235000010453 Pterocarpus marsupium Nutrition 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 24
- 239000008280 blood Substances 0.000 description 24
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 239000003146 anticoagulant agent Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 210000004623 platelet-rich plasma Anatomy 0.000 description 12
- 241000700159 Rattus Species 0.000 description 9
- 239000002158 endotoxin Substances 0.000 description 9
- 239000002024 ethyl acetate extract Substances 0.000 description 9
- 230000002785 anti-thrombosis Effects 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 6
- 206010002091 Anaesthesia Diseases 0.000 description 6
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 6
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 6
- 230000037005 anaesthesia Effects 0.000 description 6
- 229960004676 antithrombotic agent Drugs 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 235000021283 resveratrol Nutrition 0.000 description 6
- 229940016667 resveratrol Drugs 0.000 description 6
- 230000002776 aggregation Effects 0.000 description 5
- 238000004220 aggregation Methods 0.000 description 5
- 230000035699 permeability Effects 0.000 description 5
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 4
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 108010058861 Fibrin Fibrinogen Degradation Products Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 230000004931 aggregating effect Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000000208 fibrin degradation product Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000012337 thromboprophylaxis Methods 0.000 description 2
- 240000000560 Citrus x paradisi Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 206010014522 Embolism venous Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000134253 Lanka Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 230000002471 thromboprophylactic effect Effects 0.000 description 1
- 238000007395 thrombosis prophylaxis Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 208000004043 venous thromboembolism Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
本発明は、血栓予防治療剤及びその製造方法に関する。 The present invention relates to an antithrombotic therapeutic agent and a method for producing the same.
血栓は、血管内の血液が何らかの原因で塊を形成し、主に血管壁が傷害されることにより起こり、血栓による疾患として血栓性静脈炎、静脈血栓塞栓症(エコノミークラス症候群)、動脈血栓塞栓症、播種性血管内凝固症候群(DIC)等が知られている。これまで血栓を治療するための薬剤が開発されており、血栓治療剤に使用される有効成分の1つとして、スチルベン誘導体が知られている。 Thrombosis is caused by blood clots in blood vessels forming a lump and injury to the blood vessel wall mainly, and thrombophlebitis, venous thromboembolism (economy class syndrome), arterial thromboembolism as diseases caused by thrombi. And disseminated intravascular coagulation syndrome (DIC) are known. Until now, drugs for treating thrombus have been developed, and stilbene derivatives are known as one of the active ingredients used for thrombus treating agents.
特許文献1には、スチルベン誘導体であり抗血栓作用を有するレスベラトロールを、ブドウ果実、果皮、種子、新芽又は茎の1つあるいは複数からなる素材から水とエタノールとの混合溶媒を用いて抽出する方法が記載されている。 In Patent Document 1, resveratrol, which is a stilbene derivative and has antithrombotic activity, is extracted from a material comprising one or more of grape fruits, peels, seeds, shoots or stems using a mixed solvent of water and ethanol How to do it is described.
しかしながら、レスベラトロールは体内への吸収率・滞留率が低く、血中滞留時間が短い。このため、近年レスベラトロールよりも体内への吸収率・滞留率が高く、血中滞留時間を長くすることで血栓予防をより有効とする治療剤が求められている。そこで本発明者らは植物インドキノキから抽出される成分を血栓予防治療剤として使用できることを発見し本発明に至ったのである。 However, resveratrol has a low absorption rate and retention rate in the body and a short residence time in blood. For this reason, in recent years, a therapeutic agent that makes thrombosis prevention more effective by resveratrol having higher absorption rate and retention rate in the body and longer residence time in blood is required. Then, the present inventors discovered that the component extracted from a plant indo-quino can be used as a thrombosis preventive treatment, and came to this invention.
本発明は、インドキノキ(Pterocarpus marsupium)の全木からアルコール抽出によって得られた抽出成分を用いることで従来よりも更に治療効果の高い血栓予防治療剤とその製造方法を提供するものである。 The present invention provides a thromboprophylactic and therapeutic agent having a therapeutic effect higher than that of the prior art and a method for producing the same, by using an extract component obtained by alcohol extraction from the whole tree of Indian quinque (Pterocarpus marsupium).
請求項1に係る発明は、植物インドキノキ(Pterocarpus marsupium)を粉末化し、この粉末からアルコール溶液による加熱抽出を行うことにより得られる抽出物を含む血栓予防治療剤に関する。
The invention according to claim 1, the plant Indokinoki the (Pterocarpus marsupium) powdered relates thromboprophylaxis therapeutic agent comprising an extract obtained by intends row heating extraction with an alcohol solution from the powder.
請求項2に係る発明は、前記アルコール溶液による加熱抽出を行うことにより得られる抽出物には、下式(1)で示されるプテロスチルベンが含まれていることを特徴とする請求項1記載の血栓予防治療剤に関する。
Invention, the extraction obtained by heating extraction with alcohol solution, according to claim 1, characterized that it contains pterostilbene represented by the following formula (1) according to claim 2 Related to antithrombotic agents for thrombosis.
請求項3に係る発明は、(1)植物インドキノキ(Pterocarpus marsupium)を粉末化する工程と、(2)(1)により得られた粉末からアルコール溶液による抽出物を抽出する工程とにより得られる抽出物を含む血栓予防治療剤の製造方法に関する。
請求項4に係る発明は、前記アルコール溶液による抽出物を抽出する工程により得られる抽出物には下式(1)で示されるプテロスチルベンが含まれていることを特徴とする請求項3記載の血栓予防治療剤の製造方法に関する。
The invention according to claim 3 is an extraction obtained by: (1) pulverizing a plant indo-quinoki (Pterocarpus marsupium); and extracting an extract from the powder obtained in (2) (1) with an alcohol solution. The present invention relates to a method for producing an antithrombotic therapeutic agent containing a substance.
The invention according to claim 4, according to claim 3, characterized in that the extract obtained by the process of extracting the extract according to the alcoholic solution contains pterostiibene represented by the following formula (1) The present invention relates to a method for producing a thrombus preventing and treating agent.
請求項1及び3に係る発明によれば、工程(1)〜(2)を経て植物インドキノキから血栓予防治療剤として有効な抽出物を得ることができる。更にこの抽出物は、血液中の粘性を低下させ血栓の発生を抑制することができることから、血栓性疾患の治療に有効な血栓予防治療剤を提供することができる。
According to the invention which concerns on Claim 1 and 3 , an extract effective as an antithrombotic therapeutic agent can be obtained from a plant indochiki through a process (1)-(2). Furthermore, since this extract can reduce the viscosity in blood and can suppress the occurrence of thrombus, it can provide an antithrombotic therapeutic agent effective for the treatment of thrombotic diseases .
請求項2及び4に係る発明によれば、アルコール溶液による加熱抽出を行うことにより得られる抽出物にはプテロスチルベンが含まれていることから、血栓性疾患の治療により有効な血栓予防治療剤を提供することができる。
According to the invention as set forth in claims 2 and 4 , since the extract obtained by performing heat extraction with an alcohol solution contains pterostilbene, a thrombus preventing and treating agent more effective for the treatment of thrombotic diseases is provided. Can be provided .
請求項5に係る発明によれば、アルコール溶液として、メタノール、エタノール、プロパノールを使用することにより、インドキノキから血栓治療剤に有効な成分を抽出することができる。
According to the fifth aspect of the present invention, by using methanol, ethanol and propanol as the alcohol solution, it is possible to extract an effective component for the antithrombotic agent from the indo-quinoqui.
本発明に係る血栓予防治療剤は以下の工程を経て得られる。
(1)植物インドキノキ(Pterocarpus marsupium)を粉末化する工程
(2)(1)により得られた粉末からアルコール溶液により抽出物を抽出する工程
(3)(2)により得られた抽出粉末から酢酸エチルに可溶する抽出物を抽出する工程
The antithrombotic therapeutic agent according to the present invention can be obtained through the following steps.
(1) Extracting the extract with an alcohol solution from the powder obtained by the step (2) (1) of pulverizing the plant indo-quinoki (Pterocarpus marsupium) (3) ethyl acetate from the extracted powder obtained by the process (3) (2) Extracting an extract soluble in water
本発明に係る血栓予防治療剤の製造方法について詳細に説明する。
先ず、工程(1)について説明する。
植物インドキノキを破砕機等により粉末化する。
インドキノキは、マメ科シタン属に属するPterocarpus marsupiumであり、インド南部からスリランカに分布する常緑樹である。このとき、粉末化するにあたって、インドキノキの幹(心材、辺材、樹皮)、枝、葉、花、根を含む全木を使用してもよいし、インドキノキの幹、枝、葉、花、根の何れか又はその組み合わせを使用してもよい。また、粉末化により得られる粉末の粒径については特に限定されない。
The method for producing the antithrombotic therapeutic agent according to the present invention will be described in detail.
First, step (1) will be described.
The plant indica is powdered by a crusher or the like.
Indo-kinokiki is Pterocarpus marsupium belonging to the leguminous genus Citan, and is an evergreen tree distributed from southern India to Sri Lanka. At this time, it is possible to use whole trees including stems (heartwood, sapwood, bark), branches, leaves, flowers, roots of indo-quinoki when powdered, or stems, branches, leaves, flowers, roots of indo-quinaki Or any combination thereof. Moreover, it does not specifically limit about the particle size of the powder obtained by pulverization.
工程(2)について説明する。
粉末化したインドキノキの粉末から水とアルコールからなる混合溶媒(アルコール溶液)を用いて、アルコール溶液に可溶する成分を得る。このとき使用されるアルコールとして、メタノール、エタノール、プロパノール等が好適に利用される。更にアルコール溶液に含まれるアルコールの含有量は30〜100%であることが好ましい。また、アルコール含有量が30%より少ないとプテロスチルベンが抽出され難くいため好ましくない。この操作にアルコール溶液を用いることで、インドキノキに含まれる血栓性疾患の治療に有効な成分を抽出することができる。更に、この抽出操作に使用する粉末化したインドキノキ及びアルコール溶液の質量比は、1:5〜20であることが好ましい。
The step (2) will be described.
Using a mixed solvent (alcohol solution) consisting of water and alcohol from powder of powdered indo-quinaki, components soluble in an alcohol solution are obtained. As the alcohol used at this time, methanol, ethanol, propanol or the like is suitably used. Furthermore, it is preferable that content of the alcohol contained in alcohol solution is 30 to 100%. If the alcohol content is less than 30%, it is not preferable because pterostilbene is difficult to extract. By using an alcohol solution for this operation, it is possible to extract an effective ingredient for treating thrombotic diseases contained in indo-quinaki. Furthermore, it is preferable that the mass ratio of the powdered indo-quinokia used for this extraction operation and an alcohol solution is 1: 5-20.
アルコール溶液に可溶する成分を含む溶液を濃縮し、濃縮液を得る。この操作により、水よりも低沸点成分であるアルコールに溶解しているインドキノキの成分の濃度を高めることができる。この操作の濃縮温度は40〜60℃であることが好ましい。この理由は成分の分解を防ぐためである。また、濃縮後の抽出液には粉末等の固体が含まれている虞があるため、濾過により取り除くことが好ましい。 The solution containing the component soluble in alcohol solution is concentrated to obtain a concentrate. By this operation, it is possible to increase the concentration of the component of the indo-quinaki dissolved in alcohol which is a component boiling lower than water. The concentration temperature in this operation is preferably 40 to 60 ° C. The reason is to prevent the decomposition of the components. Moreover, since there is a possibility that solids such as powder are contained in the extract after concentration, it is preferable to remove by filtration.
工程(3)について説明する。
工程(2)により得られた濃縮液を減圧乾燥器等による減圧乾燥により、抽出粉末(固体の抽出物)が得られる。このとき、減圧乾燥に使用される装置については特に限定されない。
The step (3) will be described.
The concentrate obtained in the step (2) is dried under reduced pressure using a vacuum drier or the like to obtain an extraction powder (extract of solid). At this time, the apparatus used for vacuum drying is not particularly limited.
得られた抽出粉末に、水及び酢酸エチルを加えて、この抽出粉末から酢酸エチルに可溶する成分を抽出する。この後、シリカゲルを用いたカラムクロマトにより目的抽出物を得る。この抽出物は、下式(1)に示されるプテロスチルベンを主成分として含んでいる(図1、2参照、下記[0040]において詳細に説明する)。 Water and ethyl acetate are added to the obtained extracted powder to extract a component soluble in ethyl acetate from the extracted powder. After this, the target extract is obtained by column chromatography using silica gel. This extract contains pterostilbene represented by the following formula (1) as a main component (see FIGS. 1 and 2 and described in detail in [0040] below).
工程(3)において、酢酸エチルを複数回に分けて加え、水中に含まれている酢酸エチルに可溶する成分(目的抽出物)を抽出してもよい。 In the step (3), ethyl acetate may be added in multiple portions to extract a component (target extract) soluble in ethyl acetate contained in water.
上記した方法により、得られた抽出物は、血液中の粘性を低下させ血栓の発生を抑制することができることから、血栓性疾患の治療に有効な血栓予防治療剤とすることができる。 According to the above-described method, the obtained extract can reduce viscosity in blood and can suppress the occurrence of thrombus, and thus can be used as a thrombus preventing and treating agent effective for treating thrombotic diseases.
本発明に係る血栓予防治療剤及びその製造方法に関する実施例を示すことにより、本発明の効果をより明確なものとする。但し、本発明はこの実施例に何ら限定されるものでない。 The effects of the present invention are made more clear by showing examples regarding the antithrombotic therapeutic agent according to the present invention and the method for producing the same. However, the present invention is not limited to this embodiment.
<血栓治療剤の作製>
インドキノキの全木(幹、枝、葉、花、根を含む)50gを粉砕器を用いて粉末化した。蒸留装置(熱源(ガスバーナー)、蒸留用フラスコ、ト字管、温度計、冷却器、冷却水、蒸留液を溜めるフラスコ)の蒸留用フラスコに、得られた粉末を50gと50%エタノール溶液500ml加えて、温度を90℃とし、インドキノキから50%エタノール溶液に可溶する成分を得て、エバポレ−タ−により液を濃縮した。これをエタノール抽出物とする。減圧蒸留により濃縮した抽出液は減圧乾燥(40℃)し、抽出粉末を得た。
分液漏斗に抽出粉末を500mg、水を50ml、そして酢酸エチルを40ml加え、酢酸エチルに可溶するする成分を抽出した。このとき、酢酸エチルは40mlずつ3回に分けて加えた(全量120ml)。この後、減圧濃縮により、酢酸エチル抽出物(血栓予防治療剤)を得た。このとき、分液漏斗に加えた水を水抽出物とした。
<Production of antithrombotic agents>
Fifty grams of the whole tree (including stems, branches, leaves, flowers, and roots) of Indian quinoki was powdered using a grinder. 50 g of the obtained powder and 500 ml of a 50% ethanol solution in a distillation flask of a distillation apparatus (heat source (gas burner), distillation flask, double-sided tube, thermometer, condenser, cooling water, flask for storing distilled water) In addition, the temperature was raised to 90 ° C. to obtain a component which is soluble in a 50% ethanol solution from an indo-quinoki, and the solution was concentrated by an evaporator. Let this be an ethanol extract. The extract concentrated by vacuum distillation was dried under reduced pressure (40 ° C.) to obtain an extracted powder.
In a separatory funnel, 500 mg of the extracted powder, 50 ml of water and 40 ml of ethyl acetate were added to extract the components soluble in ethyl acetate. At this time, ethyl acetate was added in three 40 ml portions (total amount 120 ml). After this, concentration under reduced pressure gave an ethyl acetate extract (a thrombosis preventive and therapeutic agent). At this time, water added to the separatory funnel was used as a water extract.
<成分分析>
本実施例における抽出粉末、及び酢酸エチル抽出物の成分は液体クロマトグラフにより分析を行った。
本実施例で用いた液体クロマトグラフ測定装置及び条件を以下に示す。
測定機器:HPLCシステム (株)島津製作所製高速液体クロマトグラフ
カラム:COSMOSIL 5C18−MS−II(4.6×250mm)
カラム温度:40℃
移動相:A相はリン酸0.1%を含む30%メタノール溶液、B相はメタノールとした。
A/B=(100/0)→A/B=(0/100)となるように30分送液。
送液速度:0.8ml/min
検出:UV(290nm)
結果を図1及び2に示す。
<Component analysis>
The components of the extract powder and ethyl acetate extract in this example were analyzed by liquid chromatography.
The liquid chromatograph measuring device and conditions used in this example are shown below.
Measuring instrument: HPLC system High-performance liquid chromatograph manufactured by Shimadzu Corporation
Column: COSMOSIL 5C18-MS-II (4.6 x 250 mm)
Column temperature: 40 ° C
Mobile phase: A phase was a 30% methanol solution containing 0.1% phosphoric acid, and B phase was methanol.
30 minutes of liquid transfer so that A / B = (100/0) → A / B = (0/100).
Liquid transfer rate: 0.8 ml / min
Detection: UV (290 nm)
The results are shown in FIGS. 1 and 2.
<エンドトキシン(LPS)誘発DIC病態ラットを用いた血液レオロジー改善作用試験>
各サンプル共に1週間予備飼育した雄性ラット(8週齢、各群7匹)を使用した。
(対照)
本試験における対照とは、健康な雄性ラットである。このラットに0.2%カルボキシメチルセルロースナトリウム(CMC・Na)を1日1回、連日7日間経口投与した。7日目投与後にペントバルビダール麻酔下にて腹部大静脈から採血した。
(担体対照)
本試験における担体対照は、LPS誘発DIC病態にさせ、血栓予防に有効である成分を投与しない。雄性ラットに0.2%カルボキシメチルセルロースナトリウム(CMC・Na)を1日1回、連日7日間経口投与した。7日目の被検体投与1時間後にLPSをペントバルビダール(睡眠薬)で軽度な麻酔下投与した。LPSの投与から4時間後にペントバルビダール麻酔下にて腹部大静脈から採血した。
(陽性対照)
本試験における陽性対照は、血栓予防に有効であることが知られている薬剤を投与する。雄性ラットに、陽性対照薬としてヘパリンを7日目のLPS投与の1時間前に投与した。LPSの投与から4時間後にペントバルビダール麻酔下にて腹部大静脈から採血した。
<A test to improve blood rheology using endotoxin (LPS)-induced DIC diseased rats>
Male rats (8 weeks old, 7 rats in each group) preliminarily fed with each sample for 1 week were used.
(Control)
Controls in this study are healthy male rats. The rats were orally administered 0.2% sodium carboxymethylcellulose (CMC.Na) once a day for 7 days a day. After administration on day 7, blood was collected from the abdominal vena cava under pentobarbidal anesthesia.
(Carrier control)
The vehicle control in this study has LPS induced DIC pathology and does not receive components that are effective in preventing thrombus. Male rats were orally administered 0.2% sodium carboxymethylcellulose (CMC · Na) once a day for 7 days a day. One hour after subject administration on day 7, LPS was administered under mild anesthesia with pentobarbidal (a sleep medicine). Four hours after administration of LPS, blood was collected from the abdominal vena cava under pentobarbidal anesthesia.
(Positive control)
The positive controls in this study receive agents known to be effective in preventing thrombus. Male rats were administered heparin as a positive control drug one hour prior to LPS administration on day 7. Four hours after administration of LPS, blood was collected from the abdominal vena cava under pentobarbidal anesthesia.
(実施例1)
酢酸エチル抽出物を50[mg/kg]に調製した被検体を1日1回7日間、連日経口投与した。7日目の被検体投与1時間後にLPSをペントバルビダール(睡眠薬)で軽度な麻酔下投与した。LPSの投与から4時間後にペントバルビダール麻酔下にて腹部大静脈から採血した。
(実施例2)
酢酸エチル抽出物を200[mg/kg]に調製した被検体を使用した以外は実施例1と同じである。
(実施例3)
酢酸エチル抽出物を500[mg/kg]に調製した被検体を使用した以外は実施例1と同じである。
Example 1
The subject prepared ethyl acetate extract at 50 [mg / kg] was orally administered once a day for 7 days on a daily basis. One hour after subject administration on day 7, LPS was administered under mild anesthesia with pentobarbidal (a sleep medicine). Four hours after administration of LPS, blood was collected from the abdominal vena cava under pentobarbidal anesthesia.
(Example 2)
The same as Example 1 except that a subject prepared by adjusting the ethyl acetate extract to 200 mg / kg was used.
(Example 3)
The same as Example 1 except that a subject prepared by adjusting the ethyl acetate extract to 500 [mg / kg] was used.
採血した血液について、血液中の血小板数、白血球数、赤血球数、血清中のフィブリノーゲン量、フィブリン分解産物(FDP)量について生化学的検査を実施した。
全血通過時間は、実施例、対照、担体対照、陽性対照の各サンプルのラットから採血したそれぞれの血液を用い、マイクロチャネルアレイBloody 6−5(幅4.5μm、長さ30μm、深さ4.5μm、8736本並列)を装填した血液流動性測定装置(MC−FAN:日立製作所製)を用いて測定した。
実施例、対照、担体対照、陽性対照の各サンプルのラットから採血したそれぞれの血液9容量に対して、3.8%クエン酸ナトリウム溶液1容量を混合したもの50μLをMC−FANに付し、20cm水柱圧下で50μLの全血通過時間を測定した。全血通過時間の測定値は、直前に測定された生理食塩水100μLの通過時間を用いて、以下の式により生理食塩水の通過時間が12.0秒の場合に換算して示した。
全血通過時間=血液通過時間(s)×12.0(s)/生理食塩水通過時間(s)
結果を表1、2に示す。
The blood collected was subjected to a biochemical examination for the number of platelets in blood, the number of white blood cells, the number of red blood cells, the amount of fibrinogen in serum, the amount of fibrin degradation product (FDP).
The whole blood passage time is determined by using the blood collected from the rat of each sample of the example, control, carrier control and positive control, and using the microchannel array Bloody 6-5 (width 4.5 μm, length 30 μm, depth 4) The measurement was carried out using a blood fluidity measurement apparatus (MC-FAN: manufactured by Hitachi, Ltd.) loaded with 5.
50 μL of one volume of 3.8% sodium citrate solution mixed with 9 volumes of each blood collected from rats of each sample of Example, Control, Carrier Control, and Positive Control is subjected to MC-FAN, 50 μL whole blood transit time was measured under 20 cm water pressure. The measurement value of the whole blood passage time was shown by converting the case where the passage time of the physiological saline was 12.0 seconds by the following equation, using the passage time of 100 μL of the physiological saline measured immediately before.
Whole blood transit time = blood transit time (s) × 12.0 (s) / saline transit time (s)
The results are shown in Tables 1 and 2.
<血小板凝集抑制試験>
(PRP懸濁液の調製)
雄性ウサギ(14週齢)の心臓から血液9容量に対して3.8%クエン酸ナトリウム溶液1容量の割合で採血した後、シリコンチューブに入れ、遠心分離(170g、10分間、25℃)し、上層の多血小板血漿(PRP)を得た。得られたPRPは別のシリコンチューブに入れた後、キャップをして室温にて保存した。さらに、下層を遠心分離(1520×g、15分間、25℃)し、その上層の乏血小板血漿(PPP)を得た。血小板数が2.5−3.5×105個/μLになるようにPRPをPPPで希釈し、PRP 懸濁液とした。PPPを透過度100%、PRP懸濁液を透過度0%の標準値に設定した。
<Platelet aggregation inhibition test>
(Preparation of PRP suspension)
Blood is collected from the heart of a male rabbit (14 weeks old) at a ratio of 1 volume of 3.8% sodium citrate solution to 9 volumes of blood, then placed in a silicon tube and centrifuged (170 g, 10 minutes, 25 ° C.) , Upper layer platelet rich plasma (PRP) was obtained. The obtained PRP was put into another silicon tube, then capped and stored at room temperature. Furthermore, the lower layer was centrifuged (1520 × g, 15 minutes, 25 ° C.) to obtain platelet-rich plasma (PPP) in the upper layer. PRP was diluted with PPP so that the platelet count would be 2.5-3.5 × 10 5 / μL, and used as a PRP suspension. The PPP was set to a standard value of 100% transmission and the PRP suspension to a transmission of 0%.
(被検液の調製)
陽性対照
本試験において陽性対照には、凝集抑制の効果がある薬剤を使用した。陽性対照薬にはインドメタシンを用い、インドメタシンをジメチルスルホキシド(DMSO)で溶解させた後、50mM Tris−HCl緩衝液(Tris−HCl buffer、1M HCl溶液でpH 7.4に調整した緩衝液)でDMSOの濃度が0.5%となるように溶解させたものを使用した。
(Preparation of test solution)
Positive Control The positive control used in the present test was a drug having an aggregation inhibitory effect. As a positive control drug, indomethacin is used, and indomethacin is dissolved in dimethyl sulfoxide (DMSO), and then 50 mM Tris-HCl buffer (Tris-HCl buffer, buffer adjusted to pH 7.4 with 1 M HCl solution) DMSO Dissolved at a concentration of 0.5% was used.
陰性対照
本試験における陰性対照には、凝集抑制に有効である成分を投与せず、50mM Tris−HCl bufferでDMSOの濃度が0.5%となるように溶解させたものを使用した。
Negative control As a negative control in the present test, a substance which was effective for inhibiting aggregation was dissolved and dissolved in 50 mM Tris-HCl buffer so that the concentration of DMSO was 0.5%.
実施例
インドキノキの粉末からエタノール溶液に可溶した成分からなる抽出物(エタノール抽出物)、酢酸エチルに可溶する成分からなる抽出物(酢酸エチル抽出物)、及び水に可溶する成分からなる抽出物(水抽出物)夫々をジメチルスルホキシド(DMSO)で溶解させた後、50 mM Tris−HCl緩衝液(Tris−HCl buffer、1 M HCl溶液でpH 7.4に調整した緩衝液)でDMSOの濃度が0.5%となるように溶解させたものを使用した。
EXAMPLE An extract consisting of a component soluble in an ethanol solution from a powder of an indo-quinaki extract (ethanol extract), an extract consisting of a component soluble in ethyl acetate (ethyl acetate extract), and a component soluble in water Extract (water extract) Each was dissolved in dimethyl sulfoxide (DMSO), and then with 50 mM Tris-HCl buffer (Tris-HCl buffer, buffer adjusted to pH 7.4 with 1 M HCl solution) Dissolved at a concentration of 0.5% was used.
比較例
従来、凝集抑制効果のあるものとして知られているプテロスチルベン、レスベラトロールについても同様の試験を行った。プテロスチルベン、レスベラトロールをジメチルスルホキシド(DMSO)で溶解させた後、50mM Tris−HCl緩衝液でDMSOの濃度が0.5%となるように溶解させたものを使用した。
Comparative Example The same test was also conducted on pterostilbene and resveratrol which are conventionally known to have an aggregation inhibitory effect. Pterostilbene and resveratrol were dissolved in dimethyl sulfoxide (DMSO), and then dissolved in 50 mM Tris-HCl buffer so that the concentration of DMSO was 0.5%.
(凝集抑制試験)
調製したPRPをアグリゴメーター(PRP313M、MC Medical Inc.)専用のキュベットに200μLずつ分注し、37℃、1000rpmで3分間攪拌した後、被検液はマイクロシリンジを用いて11 μL添加した。さらに37℃、1000rpmで3分間保温撹拌した後、凝集剤としてコラーゲン(100μg/mL、希釈液に溶解)をマイクロシリンジで11μL添加した。血小板凝集によって生じるPRP懸濁液の透過度の変化は、凝集剤添加後10分間、アグリゴメーターを用いて記録した。血小板凝集率(%)は凝集剤添加後10分間における最大透過度の増加量として評価した。透過度はPRP懸濁液を0%、PPPを100%に設定した。被検体の血小板凝集率は対照群の最大透過度に対する被検体の最大透過度の減少割合とした。
結果を表3、4に示す。
(Aggregation suppression test)
200 μL each of the prepared PRP was dispensed in a cuvette dedicated to an aggregometer (PRP 313M, MC Medical Inc.) and stirred at 37 ° C. and 1000 rpm for 3 minutes, and then 11 μL of a test solution was added using a microsyringe. The mixture was further incubated and stirred at 37 ° C. and 1000 rpm for 3 minutes, and then 11 μL of collagen (100 μg / mL, dissolved in a diluted solution) was added as a coagulant by a microsyringe. The change in permeability of PRP suspension caused by platelet aggregation was recorded using an aggregometer for 10 minutes after addition of the aggregating agent. The platelet aggregation rate (%) was evaluated as an increase in maximum permeability in 10 minutes after addition of the aggregating agent. The permeability was set to 0% for the PRP suspension and 100% for the PPP. The platelet aggregation rate of the subject was taken as the decreasing rate of the maximum permeability of the subject to the maximum permeability of the control group.
The results are shown in Tables 3 and 4.
<血栓予防治療剤の調製結果>
図1及び2において、縦軸はピーク強度、横軸はリテンションタイムを示している。このとき、リテンションタイム28.14[min]に示されるピークは、プテロスチルベンのピークである。
図1に示すように、エタノール溶液を抽出液として使用することで、インドキノキの粉末からプテロスチルベンを主成分とする抽出物を抽出することができた。また、図2に示すように、図1よりもプテロスチルベンを示すピークが高くなっていることから、抽出粉末から、エタノール蒸留により得られた抽出物を酢酸エチルで更に分画することで、目的抽出物を選択的に得ることができた。
<Results of preparation of antithrombotic agent>
In FIGS. 1 and 2, the vertical axis represents peak intensity, and the horizontal axis represents retention time. At this time, the peak indicated by retention time 28.14 [min] is a peak of pterostilbene.
As shown in FIG. 1, by using an ethanol solution as an extract, it was possible to extract an extract containing pterostilbene as a main component from a powder of an indo-quinaki. Further, as shown in FIG. 2, since the peak showing pterostilbene is higher than that in FIG. 1, the objective is to further fractionate the extract obtained by ethanol distillation from the extraction powder with ethyl acetate. An extract could be obtained selectively.
<血液レオロジー改善作用試験結果>
表1の実施例に示されるように、目的抽出物の投与量が多くなる毎に、全血通過時間が短縮されていることが分かる。この結果から、インドキノキからアルコール溶液を用いて抽出した酢酸エチル抽出物(目的抽出物)は、血液の粘性を低下させる働きがあることが分かった。
<Results of blood rheology improvement effect test>
As shown in the example of Table 1, it can be seen that the whole blood passage time is shortened as the target extract dose increases. From this result, it was found that the ethyl acetate extract (the target extract) extracted from the indo-quinaki with an alcohol solution has a function to reduce the viscosity of blood.
<血小板凝集抑制試験結果>
表3に示すように、エタノール溶液から抽出した抽出物(エタノール抽出物)、及び酢酸エチルに可溶する成分から得られた抽出物(酢酸エチル抽出物)は血小板が凝集する割合が低いことが分かる。
レスベラトールとプテロスチルベンは血小板の凝集率を下げる効果があることが知られている。表4に示すように、プテロスチルベン単独でも効果はあるが、インドキノキから抽出された酢酸エチル抽出物(目的抽出物)の方が効果に優れている。これは、インドキノキから抽出される抽出物に凝集率を下げる効果のある成分がプテロスチルベン以外にも含まれているためと考えられる。
<Platelet aggregation inhibition test result>
As shown in Table 3, the extract extracted from the ethanol solution (ethanol extract) and the extract obtained from the component soluble in ethyl acetate (ethyl acetate extract) have a low platelet aggregation rate I understand.
Resveratrol and pterostilbene are known to be effective in reducing platelet aggregation. As shown in Table 4, although pterostilbene alone is effective, the ethyl acetate extract (target extract) extracted from indo-quinaki is more effective. This is considered to be due to the fact that the extract having an effect of reducing the aggregation rate is contained in the extract extracted from Indian quinque besides pterostilbene.
本発明に係る血栓予防治療剤及びその製造方法により、インドキノキを抽出することにより得られる抽出物は、血栓性疾患における血栓予防治療剤について好適に利用される。 The extract obtained by extracting an indo-quinaki by the antithrombotic agent and therapeutic agent according to the present invention and the method for producing the same is suitably used for an antithrombotic agent for thrombotic diseases.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014167862A JP6523634B2 (en) | 2014-08-20 | 2014-08-20 | Thrombus preventive and therapeutic agent and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014167862A JP6523634B2 (en) | 2014-08-20 | 2014-08-20 | Thrombus preventive and therapeutic agent and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016044134A JP2016044134A (en) | 2016-04-04 |
JP6523634B2 true JP6523634B2 (en) | 2019-06-05 |
Family
ID=55635019
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014167862A Active JP6523634B2 (en) | 2014-08-20 | 2014-08-20 | Thrombus preventive and therapeutic agent and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6523634B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109803644A (en) | 2016-09-26 | 2019-05-24 | 学校法人圣玛丽安娜医科大学 | Ovarian function reduces prevention or improver |
CN108478660A (en) * | 2018-05-30 | 2018-09-04 | 河南金凤生物科技有限公司 | A kind of Chinese medicine preparation and preparation method thereof for treating blood vessel blockage |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101530454B (en) * | 2008-03-11 | 2014-12-17 | 北京富华安德生物医药科技开发有限公司 | Applications of pterocarpus indicus extract on inhibition of blood platelet aggregation |
US9737495B2 (en) * | 2009-06-22 | 2017-08-22 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
CN102319233B (en) * | 2011-07-13 | 2013-07-03 | 河南工业大学 | Application of pterostilbene in inhibiting vascular endothelial apoptosis |
US20130072509A1 (en) * | 2011-09-15 | 2013-03-21 | ChromaDex Inc. | Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation |
-
2014
- 2014-08-20 JP JP2014167862A patent/JP6523634B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2016044134A (en) | 2016-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5352655B2 (en) | Pharmaceutical preparation comprising a phenylethanoid glycoside extracted from a herbaceous plant, the all parasitic plant of the family Amaranthaceae [CISTANCHETUBULOSA (SCHENK.) WIIGHT], method for producing the same, and use thereof | |
JP4892690B2 (en) | Hepatitis C virus production inhibitor | |
CN106214674B (en) | The medical usage of 7- hydroxyls-butylphenyl phthaleine | |
KR20090034401A (en) | Eucalyptus extract, method of preparation and therapeutic uses thereof | |
WO2014014271A1 (en) | Tablet comprising melissa officinalis folium extract for preventing or treating angiogenesis or mmp activity-mediated disease | |
Onaran et al. | Successful treatment of sodium oxalate induced urolithiasis with Helichrysum flowers | |
KR20200097303A (en) | Diterpene Zincolide Composition | |
JP2010155840A (en) | Pharmaceutical composition for treating hepatitis b and health food having hepatitis b virus inhibiting effects | |
JP6523634B2 (en) | Thrombus preventive and therapeutic agent and method for producing the same | |
JPH07258103A (en) | Antithrombosis agent and its preparation | |
Alamgeer et al. | Alkaloids, flavonoids, polyphenols might be responsible for potent antiarthritic effect of Solanum nigrum | |
CN108042661B (en) | White tea extract rich in dihydromyricetin and application thereof in preparing medical health products | |
US20100173028A1 (en) | Process for preparing vitis vinifera pip extract and pharmaceutical composition for preventing or treating rheumatoid arthritis comprising the same | |
JP2016128434A (en) | Production method of natural benzaldehyde water, natural benzaldehyde water produced by production method, and antitumor agent containing natural benzaldehyde water | |
KR101407889B1 (en) | Fraxinus rhynchophylla Hance extracts compositions for treating or preventing inflammatory diseases | |
KR101881653B1 (en) | Process for Extracts of Enhancing Blood Circulation from red bean shell and Compositions comprising the Extracts as an active ingredient | |
Marref et al. | Acute Toxicity, Anti-ulcer and Anti-inflammatory Effects of Methanol Extract of Gladiolus segetum in Rats | |
CN102961499A (en) | Traditional Chinese medicine nigrum fruit product and preparation method and application thereof | |
Frye et al. | Extraction, identification, and quantification of harmala alkaloids in three species of Passiflora | |
JP2011021033A (en) | Anti-fatigue agent | |
CN112220847A (en) | Fresh pomelo flesh water extract powder, preparation, antithrombotic effect and application thereof | |
KR100779026B1 (en) | Osmanthus heterophylla extracts compositions for treating or preventing inflammatory diseases | |
KR100247569B1 (en) | Pharmaceutical compositions for anti-thrombosis | |
RU2223110C1 (en) | Anti-ischemic vegetable preparation "melilotin" and method for its preparing | |
KR20140123658A (en) | Anti-inflammatory and antioxidative composition containing Safflower Buddings extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170724 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180530 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181025 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181211 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190403 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190426 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6523634 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |